Angiotensin 17 mediates renoprotection against diabetic nephropathy by reducing oxidative stress, inflammation, and lipotoxicity
35 If the sUA target cannot be achieved with an XOI, treatment guidelines recommend combination therapy of an XOI with a uricosuric medication
Cost-benefit analysis Research cagrilintide monotherapy: Cost: $800-1,600/month Weight loss: 10-12% over 68 weeks Total investment: $12,000-24,000 (18 months) Per pound lost (220 lb person, 24 lbs): $500-1,000/lb CagriSema combination: Cagrilintide: $800-1,600/month Semaglutide: $150-300/month Total: $950-1,900/month Weight loss: 15-25% (33-55 lbs for 220 lb person) Total investment: $14,000-28,000 (18 months) Per pound lost: $250-850/lb Better value than monotherapy Comparison to bariatric surgery: Surgery: $15,000-25,000 upfront Weight loss: 25-35% One-time cost Permanent anatomical change CagriSema approaching surgery results without surgery Making it more affordable: Use maintenance doses after titration (lower cost) Consider semaglutide alone initially (cheaper, effective) Add cagrilintide if plateau Budget long-term (12-18 months minimum) Use our peptide cost calculator at SeekPeptides to budget your weight loss protocol accurately
And this was cagrilintide alone, without any GLP-1 agonist combination
Their issue is that no one reviewed it and it was completely inaccurate
